2023 Improved post-transplant outcomes in recent years for AML patients with FLT3-ITD and wild-type NPM1: a report from the EBMT acute leukemia working party Group Acute Leukemia Working Party (ALWP) 1st listed author Ali Bazarbachi Journal Clin Cancer Res.
2023 Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Jaime Sanz Journal Bone Marrow Transplant.
2023 Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal J Hematol Oncol.
2023 Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Bone Marrow Transplant.
2023 Impact of measurable residual disease on outcomes of unrelated donor haematopoietic cell transplantation with post-transplant cyclophosphamide in AML in first complete remission Group Acute Leukemia Working Party (ALWP) 1st listed author Arnon Nagler Journal Br J Haematol.
2023 Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis Group Acute Leukemia Working Party (ALWP) 1st listed author Sjoerd J F Hermans Journal Hemasphere.
2023 GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Frédéric Baron Journal J Hematol Oncol.
2023 Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Group Acute Leukemia Working Party (ALWP) 1st listed author Sebastian Giebel Journal Am J Hematol.
2023 Comorbidities in transplant recipients with acute myeloid leukemia receiving low-intensity conditioning regimens: an ALWP EBMT study Group Acute Leukemia Working Party (ALWP) 1st listed author Joshua A Fein Journal Blood Adv.
2023 Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP) Group Acute Leukemia Working Party (ALWP) 1st listed author Eleni Gavriilaki Journal Bone Marrow Transplant.
2023 Significance of Degree of HLA Disparity Using T-cell Replete Peripheral Blood Stem Cells From Haploidentical Donors With Posttransplantation Cyclophosphamide in AML in First Complete Hematologic Remission: A Study of the Acute Leukemia Working Party of the EBMT Group Acute Leukemia Working Party (ALWP) 1st listed author Mohamed A Kharfan-Dabaja Journal Hemasphere.
2023 Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) Group Acute Leukemia Working Party (ALWP) 1st listed author Enrico Maffini Journal Bone Marrow Transplant.